• Mashup Score: 1

    The addition of the CTLA-4 inhibitor tremelimumab to durvalumab and chemotherapy in the first-line setting has already demonstrated an overall survival and progression-free survival benefit vs chemotherapy alone in patients with metastatic non–small cell lung cancer (NSCLC). According to data presented at the International Association for the Study of Lung Cancer (IASLC) 2022 World Conference on…

    Tweet Tweets with this article
    • Exploratory Analysis of POSEIDON: Chemoimmunotherapy Regimen May Offer Survival Benefit in Subgroups of Metastatic NSCLC https://t.co/fHK4E8RLRe #WCLC22 #WCLC2022 #LCSM #lungcancer #oncology #immunotherapy

  • Mashup Score: 0

    Lung cancer screening has been shown to significantly reduce lung cancer mortality, but some management protocols have more benefit than others, according to data presented at the International Association for the Study of Lung Cancer 2022 World Conference on Lung Cancer (WCLC).1 Although the Dutch-Belgian lung cancer screening trial Nederlands-Leuvens Longkanker Screenings Onderzoek (NELSON)…

    Tweet Tweets with this article
    • NELSON vs NLST: Nodule Management Based on Volumetry Shows Increased Benefits https://t.co/eibVIcnRPR #LCSM #lungcancer #oncology #WCLC22 #WCLC2022

  • Mashup Score: 6

    Most women with lung cancer reported some degree of sexual dysfunction following diagnosis, according to study results presented during International Association for the Study of Lung Cancer World Conference on Lung Cancer. The findings of the cross-sectional, international Sexual Health Assessment in Women with Lung Cancer (SHAWL) survey study suggested the need for sexual health to be

    Tweet Tweets with this article
    • NEW from @IASLC #WCLC2022 Most women with lung cancer reported some degree of sexual dysfunction following diagnosis. We spoke with @NarjustFlorezMD of @DanaFarber about the findings and their implications. https://t.co/112e74iFGS https://t.co/sciiCiHViS